source
- Bausch + Lomb CEO Brent Saunders abruptly departs after failed multibillion-dollar saleBrent Saunders, known as a leading dealmaker and one of the highest-paid executives in biopharma, has left his role as chief executive of Bausch + Lomb. His departure ends a second stint as CEO of…
- AstraZeneca attributes Phase 3 failure of bone disease enzyme therapy to trial design flawsAstraZeneca disclosed that its Phase 3 study of an enzyme replacement therapy for a rare genetic bone disorder did not meet its primary objectives. The company said the shortfall was largely due t…